Trials / Completed
CompletedNCT03859700
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- DBV Technologies · Industry
- Sex
- All
- Age
- 2 Years – 5 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, follow-up study for subjects who completed the EPITOPE study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DBV712 250 mcg | DBV712 250 mcg, once daily |
Timeline
- Start date
- 2018-12-06
- Primary completion
- 2025-05-13
- Completion
- 2025-05-13
- First posted
- 2019-03-01
- Last updated
- 2025-06-06
Locations
26 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03859700. Inclusion in this directory is not an endorsement.